CWHM-12

CWHM-12是αV整联蛋白的有效抑制剂，抑制αvβ8，αvβ3，αvβ6和αvβ1的 IC₅₀ 值分别为0.2，0.8，1.5，1.8 nM。Mice are treated with CCl₄ for 3 weeks to establish fibrotic disease and then treated with CWHM-12 (CWHM 12) or vehicle for the final 3 weeks of CCl₄. CWHM-12 significantly reduces liver fibrosis even after fibrotic disease have been established. Digital image quantitation demonstrates significantly reduced p-SMAD3 signaling in the livers of CWHM-12 treated mice compare to controls, demonstrating that the protection from CCl₄-induced hepatic fibrosis observed in CWHM-12 treated mice is due at least in part to a reduction in TGF-β activation by αv integrins. Besides, administration of CWHM-12 significantly inhibited progression of pulmonary fibrosis